Lim A, Verrier T, Vosshenrich C, Di Santo J. Developmental options and functional plasticity of innate lymphoid cells. Curr Opin Immunol. 2017;44:61–68. PMID: 28359987

Tang Y, Kang Y. Microbial metabolite as icebreaker for immunotherapy. Cell Metab. 2022;34(4):506–507. PMID: 35385701

Pérez-Núñez I, Rozalén C, Palomeque J, Sangrador I, Dalmau M, Comerma L, Hernández-Prat A, Casadevall D, Menendez S, Liu D, Shen M, Berenguer J, Ruiz I, Peña R, Montañés J, Albà M, Bonnin S, Ponomarenko J, Gomis R, Cejalvo J, Servitja S, Marzese D, Morey L, Voorwerk L, Arribas J, Bermejo B, Kok M, Pusztai L, Kang Y, Albanell J, Celià-Terrassa T. LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer. Nat Cancer. 2022;3(3):355–370. PMCID: 5391692

Esposito M, Ganesan S, Kang Y. Emerging strategies for treating metastasis. Nat Cancer. 2021;2(3):258–270. PMCID: PMC8064405

Aiello-Couzo N, Kang Y. A bridge between melanoma cell states. Nat Cell Biol. 2020;22(8):913–914. PMID: 32753670

Zhang Y, Kurupati R, Liu L, Zhou X, Zhang G, Hudaihed A, Filisio F, Giles-Davis W, Xu X, Karakousis G, Schuchter L, Xu W, Amaravadi R, Xiao M, Sadek N, Krepler C, Herlyn M, Freeman G, Rabinowitz J, Ertl H. Enhancing CD8 T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. Cancer Cell. 2017;32(3):377–391.e9. PMCID: PMC5751418

Li Z, Kang Y. Emerging therapeutic targets in metastatic progression: A focus on breast cancer. Pharmacol Ther. 2016;161:79–96. PMCID: PMC4851893